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SUMMARY
Loperamide is the most commonly used antidiarrhoeal
medication in the UK. We report a serious and hitherto
undocumented adverse effect of chronic use in a 45-
year-old man with inflammatory bowel disease. He
presented to the endocrine clinic with fatigue and low
libido; biochemical assessment revealed hypogonadism
and adrenal insufficiency without any elevated
adrenocorticotropic hormone. When symptoms allowed,
loperamide was reduced and a short synacthen test (SST)
showed a ‘clear pass’ with a normal peak cortisol of
833 nmol/L. Later, worsening diarrhoea necessitated an
escalation in loperamide use again. While taking a daily
dose of 15–20 mg (recommended daily maximum
16 mg) reassessment revealed a fall in peak cortisol on
SST to 483 nmol/L, a subnormal response. Clinicians
should exercise caution when relying on loperamide to
manage their patients’ chronic diarrhoea and remain
mindful of the possibility of drug-induced life-threatening
adrenal insufficiency.
BACKGROUND
Loperamide, a phenylpiperidine derivative and a
potent opioid μ-receptor agonist, is the most com-
monly used antidiarrhoeal medication in the UK.
About 1.79 million prescriptions were issued in
20141 and it is also freely available ‘over the
counter’. Its popularity persists due to a combin-
ation of favourable efficacy and a reasonably
limited side effect profile; predictable gastrointes-
tinal side effects do occur, but it is widely consid-
ered to be a very safe and well-tolerated
medication.
Loperamide is directly absorbed into the gut
wall, exerting its effect on the myenteric plexus to
reduce propulsive activity and increase intestinal
transit time. Although gastrointestinal tract absorp-
tion is favourable, it is rapidly extracted by hepatic
cytochrome P450 metabolism resulting in low
levels in the systemic circulation (bioavailabil-
ity<2%).2 While extensively used in acute diar-
rhoea, a significant proportion of patients with
chronic gastrointestinal disease take loperamide on
a daily basis, often at relatively high doses. Prior
studies have paid scant attention to the potential
adverse effects of longer term ingestion.
We report a serious and hitherto undocumented
adverse effect of chronic loperamide use following
presentation to the endocrine clinic.
CASE PRESENTATION
A 45-year-old man presented with profound
fatigue and loss of libido. A total colectomy with
rectal pouch formation had been performed
2 years previously for ulcerative colitis. For a
minimum of 6 months, the patient had been man-
aging his chronic diarrhoea by taking loperamide
in doses totalling 40–50 mg daily (recommended
maximum dose 16 mg/day). No steroids had been
used in the management of his inflammatory
bowel disease for at least 2 years and there was no
clinical concern that he was otherwise ingesting
any corticosteroid. His only other medication was
fluoxetine 20 mg and nefopam 60 mg three times
a day.
INVESTIGATIONS
On initial assessment, biochemical testing revealed
hypogonadism with a morning serum testosterone
of 2.9 nmol/L (reference range 9–25). Profound
fatigue prompted assessment of his hypothalamic–
pituitary–adrenal (HPA) axis; following adminis-
tration of 250 mg of synacthen (tetracosactide;
adrenocorticotropic hormone (ACTH1–24)) his
peak serum cortisol was subnormal at 243 nmol/L
(table 1). In the context of his gonadal failure and
adrenal insufficiency, plasma ACTH and gonadotro-
pins were measured and found to be inappropri-
ately within the normal range (ACTH 20 ng/L,
luteinising hormone 3.1 U/L, follicle-stimulating
hormone 2.0 IU/L), indicating pituitary dysfunc-
tion. Serum-free thyroxine, thyroid-stimulating
hormone and prolactin were within reference
range. A pituitary MRI revealed no structural
abnormality which could account for this second-
ary adrenal failure and hypogonadism. He started
hydrocortisone and testosterone replacement with
rapid improvement in his symptoms.
Reassessment of HPA axis functioning was
limited by his reliance on loperamide for symptom
control and steroid replacement for adrenal failure.
More than 2 years later, pouch inflammation was
treated with antibiotics and an improvement in
diarrhoeal symptoms facilitated a temporary reduc-
tion in loperamide to 4–6 mg daily for a 48-hour
period. On this dose of loperamide, a repeat
synacthen test showed a ‘clear pass’ with a normal
peak cortisol of 833 nmol/L. Over subsequent
months, worsening diarrhoea necessitated an escal-
ation in loperamide use again. While taking a daily
dose of 15–20 mg, biochemical reassessment
revealed a fall in peak cortisol following synacthen
to 483 nmol/L, a subnormal response. Assessment
of HPA functioning at the time of increased
symptom severity, but before escalation of lopera-
mide, would have provided useful insights into
whether or not his deteriorating physical health
contributed to HPA axis suppression.
Unfortunately, the severity of his symptoms meant
this was not clinically feasible.
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OUTCOME AND FOLLOW-UP
This symptomatic deterioration has resulted in sustained use of
high-dose daily loperamide. The patient continues on steroid
replacement and testosterone replacement.
DISCUSSION
It is well recognised that potent opioids, used either as analgesic
medications or for illicit recreation, may produce dose-related
hypopituitarism, including clinically significant hypoadrenalism
and male hypogonadism.3 4 For illustration, 74% of community
dwelling men taking strong opioids (≥20 mg morphine daily or
equivalent) had a total serum testosterone concentration below
the reference range in a previous study.5 Similarly, secondary
adrenal failure has been frequently reported during both short-
term and chronic opioid administration.6–8 Opioids act centrally
to suppress the hypothalamic release of the hormones
corticotropin-releasing hormone (CRH) and gonadotropin-
releasing hormone, leading to the downstream effects of hypoa-
drenalism and hypogonadism.
Although clinically manifest hypopituitarism in the setting of
loperamide use has not been previously described, the effects of
this drug on human HPA physiology were first reported in 1986
when it was found to inhibit plasma ACTH levels in a small
number of patients with Addison’s disease. 16 mg of oral
loperamide induced a marked fall in ACTH levels that was
detectable 1-hour postdose and persisted for several hours after
administration, with a nadir at 300 min.9 Similar reductions in
basal and CRH-stimulated ACTH have also been demonstrated
in normal persons.10 Plasma levels of ACTH were markedly
suppressed 3 hours after oral ingestion of 16 mg of loperamide,
with both studies supporting a hypothalamic–pituitary mechan-
ism for the effects observed in our patient.
While adrenal failure in the context of loperamide has not
previously been reported, the overlapping chemical structure of
this drug with opioids supports the mechanism of secondary
adrenal failure seen here with high-dose loperamide.
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Table 1 The dose–response relationship: stimulated cortisol
results on variable doses of loperamide
October 2012 February 2015 May 2015
Daily loperamide dose 50 mg 6 mg 20 mg
Response to synacthen Serum cortisol (nmol/L)*
Baseline 135 604 186
30 min 191 766 385
60 min 243 833 483
Plasma ACTH (ng/L)†
Baseline 20 64 13
The synacthen (tetracosactide) tests performed in 2015 were carried out 30 hours
after the previous dose of hydrocortisone had been taken.
*Normal peak cortisol response to synacthen (tetracosactide) is 550 nmol/L or more.
†Reference range for plasma ACTH is 10–55 ng/L.
ACTH, adrenocorticotropic hormone.
Learning points
▸ Adrenal failure secondary to hypopituitarism is a serious and
hitherto unrecognised side effect of this very commonly used
medication.
▸ Critically, it was demonstrable in this patient while taking a
quantity of loperamide just marginally higher than the
maximum recommended dose.
▸ Failure to recognise adrenal failure in this setting, where
warning symptoms and signs (eg, hyponatraemia,
hypotension) may overlap with either acute or chronic
gastrointestinal disease, could have a disastrous impact.
▸ Opioids, used more commonly at higher doses with
significant systemic absorption than loperamide, can cause
dose-related hypopituitarism and clinically significant adrenal
failure.
▸ It is imperative that clinicians exercise caution when relying
on loperamide to manage their patients’ chronic diarrhoea;
we should be mindful of the possibility of drug-induced
life-threatening adrenal insufficiency.
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